The eAF (DADI) newsletter is published four times a year and provides pharmaceutical companies and the national competent authorities in the EU with updates on the progress of the eAF (DADI) project.
This second issue covers topics such as:
- Web-based Human Variations eAF: Training material, Release Notes and Q&A Documents
- Reschedule of UAT and releases of eAF during 2023
- PMS: SMEs nomination and Priorities for Q4 2022
You can find the complete second issue of the newsletter here.